Chieh-Lung ChengJIA-HAU LIUSHENG-CHIEH CHOUMING YAOJIH-LUH TANGHWEI-FANG TIEN2020-12-092020-12-092018-0709024441https://scholars.lib.ntu.edu.tw/handle/123456789/525048To investigate the effectiveness of 2 chemotherapeutic regimens, bendamustine plus rituximab (BR) or reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (RD-R-CHOP), in elderly patients with treatment-naïve diffuse large B-cell lymphoma.enbendamustine; diffuse large B-cell lymphoma; elderly patients; prognosis; reduced-dose R-CHOP[SDGs]SDG3bendamustine; cyclophosphamide; doxorubicin; prednisone; rituximab; vincristine; antineoplastic agent; bendamustine; cyclophosphamide; doxorubicin; prednisone; rituximab; vincristine; aged; anemia; Article; cancer patient; clinical article; clinical effectiveness; combination chemotherapy; controlled study; diffuse large B cell lymphoma; drug efficacy; drug safety; febrile neutropenia; female; follow up; hepatitis B; human; leukopenia; long term survival; lymphocytopenia; male; neutropenia; neutrophil count; outcome assessment; overall survival; platelet count; positron emission tomography; primary medical care; priority journal; prophylaxis; remission; retrospective study; supraventricular tachycardia; thrombocytopenia; treatment response; very elderly; cancer staging; diffuse large B cell lymphoma; mortality; pathology; survival analysis; treatment outcome; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Staging; Prednisone; Remission Induction; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vincristine10.1111/ejh.1306929603428WOS:000435935800004